| NCT ID | NCT07291687 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baycrest |
| Condition | Progressive Supranuclear Palsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-10-30 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation. In the proposed study, the investigation will assess whether walking sessions combined with tDCS lead to improvements in motor function: gait, articulation, eye gaze, and motor dexterity. In addition, the investigators wish to examine if such results can be replicated in people with other conditions, such as cortical basal syndrome, and Parkinson's disease.
Eligibility Criteria
Inclusion Criteria: \- 1. Participants must be able to walk unassisted, or with the assistance of a walker or cane, and be individuals who walk daily. 2\. Participants should have a sufficient level of English to be able to express themselves verbally, be able to read and follow instructions. Exclusion Criteria: * 3\. Individuals with metal implants within the brain such as shunts will be excluded.
Contact & Investigator
Tyler Roncero, Ph.D
PRINCIPAL INVESTIGATOR
Baycrest Academy of Health Sciences and Geriatric Research
Frequently Asked Questions
Who can join the NCT07291687 clinical trial?
This trial is open to participants of all sexes, studying Progressive Supranuclear Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07291687 currently recruiting?
Yes, NCT07291687 is actively recruiting participants. Contact the research team at azhang4@research.baycrest.org for enrollment information.
Where is the NCT07291687 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07291687 clinical trial?
NCT07291687 is sponsored by Baycrest. The principal investigator is Tyler Roncero, Ph.D at Baycrest Academy of Health Sciences and Geriatric Research. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.